TRPA1 Channel Activation Inhibits Motor Activity In The Mouse Colon by Hassan, Abdul-Azim et al.
fnins-14-00471 May 25, 2020 Time: 12:43 # 1
ORIGINAL RESEARCH















This article was submitted to
Autonomic Neuroscience,
a section of the journal
Frontiers in Neuroscience
Received: 27 November 2019
Accepted: 16 April 2020
Published: 27 May 2020
Citation:
Hassan A-A, Sleet B, Cousins Z
and Keating CD (2020) TRPA1
Channel Activation Inhibits Motor
Activity in the Mouse Colon.
Front. Neurosci. 14:471.
doi: 10.3389/fnins.2020.00471
TRPA1 Channel Activation Inhibits
Motor Activity in the Mouse Colon
Abdul-Azim Hassan, Ben Sleet, Zoe Cousins and Chris David Keating*
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There is a growing awareness of the role that TRP channels play in regulating sensory
and motor functions in the gastrointestinal tract. In this study we used an in-vitro
murine model of colonic peristaltic-like complexes (CPMCs) to evaluate the role of
exogenous and endogenous TRPA1 signaling processes in regulating colonic motility.
Using in-vitro recordings of intraluminal pressure to monitor the presence of CPMCs
in colonic segments we performed a series of experiments on male CD1 mice (2
months of age) and found that CPMC activity was attenuated by TRPA1 agonists.
Bath application of the TRPA1 antagonist HC-030031 had no effect upon basal
CPMC activity whereas application of the synthetic TRPA1 agonist ASP7663 caused
a reversible dose dependent decrease in CPMC frequency that was blocked by HC-
030031. Cinnamaldehyde and 4-hydroxy-2-nonenal elicited long lasting decreases in
CPMC frequency that were blocked by HC-030031 whereas the decreased CPMC
activity invoked by AITC could not be blocked by HC-030031. Our results show that any
potential mechanosensory function of TRPA1 doesn’t involve contributing to distension
induced colonic motor activity and that a role for TRPA1 in the colon is through regulating
motility through exogenous and endogenous agonist induced inhibitory effects.
Keywords: TRPA1, motility, colon, HNE (4-hydroxy-2-nonenal), enteric nervous system, transient receptor
channels
INTRODUCTION
The transient receptor potential (TRP) family is a group of excitatory cation channels expressed
in multiple cell types within the body that act as environmental sensors to noxious chemical,
thermal and mechanical stimuli (Ramsey et al., 2006). An important member of this super family
is the transient receptor potential ankyrin 1 (TRPA1), initially described as a cold sensitive non-
selective cation channel, but now acknowledged to have multiple physiological roles (Story et al.,
2003; Bandell et al., 2004; Nagata et al., 2005). In addition to thermal stimuli, TRPA1 has been
shown to be activated by a wide range of chemicals including nutrient derived compounds such
as allyl isothiocyanate (AITC), cinnamaldehyde (CMA), and allicin that are found in mustard,
cinnamon and garlic, respectively, as well as acrid chemicals including acrolein and tear gas. These
compounds are believed to activate the channel through a process of modifying specific cysteine
or lysine residues contained within the amino terminus of the protein (Hinman et al., 2006;
Abbreviations: AITC, allyl isothiocyanate; CMA, cinnamaldehyde; CPMCs, colonic peristaltic motor complexes; DSS,
dextran sodium sulfate; EEC, enteroendocrine cell; EC, enterochromaffin; GI, gastrointestinal; HEK, human embryonic
kidney; HNE, 4-hydroxy-2-nonenal; IP, intraluminal pressure; L-NAME, NG-nitro-L-arginine methyl ester; TIQ, time
in quiescence; TRP, transient receptor potential; TRPA1, transient receptor potential ankyrin 1; TRPA1-IR, TRPA1
immunoreactivity.
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Macpherson et al., 2007; Clapham, 2015). In addition
to exogenous agonists, TRPA1 can also be activated by
endogenous chemicals including 4-hydroxy-2-nonenal (HNE),
an inflammatory mediator produced through oxidative stress
(Esterbauer et al., 1991) providing evidence that TRPA1 is
capable of transducing inflammatory derived signals into cellular
responses (Trevisani et al., 2007).
Within the gastrointestinal tract TRPA1 is expressed on
the terminals of visceral sensory afferents and acts as a
mechanotransducer. TRPA1 activation is thought to be a
contributing factor in the generation of afferent mechano-
hypersensitivity seen in models of colitis (Brierley et al., 2009).
This role of TRPA1 is enhanced in inflammatory conditions
associated with visceral hyperalgesia suggesting that a function
of TRPA1 is as a sensor of inflammation. TRPA1 is also
activated by the release of inflammatory mediators when tissue
injury occurs or in diseased states. This dual function of
TRPA1 as a detector and instigator of inflammatory agents
makes TRPA1 a “gatekeeper” of chronic inflammatory disorders
(Bautista et al., 2013).
TRPA1 is also expressed in enterochromaffin (EC) cells in the
enteric mucosa where they exhibit a graded expression profile
along the length of the gut and are absent from the colon
(Cho et al., 2014). TRPA1 is also expressed within myenteric
neurons of the gastrointestinal tract where their expression is
strongest in nitrergic neurons the colon (Poole et al., 2011).
The broad expression profile and promiscuous activation of
this channel suggests that TRPA1 is uniquely positioned to
respond to luminal or inflammatory stimuli and is involved in
mediating a wide range of physiological and pathophysiological
events in the gastrointestinal tract. TRPA1 activation gives rise
to varied physiological responses depending on the region of gut
exposed to TRPA1 compounds, and their route of administration.
Application of TRPA1 agonists to myenteric neurons activates
them: luminal application of TRPA1 agonists in the small
intestine is excitatory, whereas serosal application in the colon
attenuates spontaneous contractile behavior (Poole et al., 2011;
Tsuchiya et al., 2016). Activation of TRPA1 channels led to
changes in contractile behavior of isolated intestinal segments
(Penuelas et al., 2007) and in-vivo changes in gastric emptying
and colonic motility (Doihara et al., 2009a,b). Activation of
TRPA1 channels located on enterochromaffin (EC) cells have
been shown to have important roles in EC cell signal transduction
(Nozawa et al., 2009; Bellono et al., 2017). Together these findings
support a role for TRPA1 in mediating motor responses of the
large intestine.
However, there is little information as to the specific effects
of TRPA1 activation on peristaltic activity in the gut. In
this study we aimed to address this question using an in-
vitro model of peristaltic-like behavior (Keating et al., 2014).
This model employs segments of mouse colon which generate
robust and stereotypic patterns of colonic peristaltic motor
complexes (CPMCs) when mounted in an organ bath and
perfused with Krebs solution (Abdu et al., 2002). The advantage
of this system is that the intestinal segments contain all the
functional components of the enteric nervous system necessary
to initiate peristaltic-like motor activity (Brookes et al., 1999) and
that CPMC activity is similar to the intestinal motor patterns
observed in vivo. For this study we assessed CPMC characteristics
(frequency and amplitude) using compounds with known effects
upon TRPA1 channel pharmacology as a way of addressing




All experiments were performed at the University of
Hertfordshire. Fifty one adult male mice (CD1, Charles
River, United Kingdom), 6–8 weeks old and weighing ˜30 g
were used. Animals were housed under controlled ambient
temperature (21 ± 2◦C) and light-dark cycle (12:12 h) and were
allowed free access to food and water. Animals were euthanized
by a gently rising concentration of carbon dioxide followed by
cervical dislocation. Animals were maintained in accordance
with Home Office regulations following the Animal and Scientific
Procedures Act 1986.
Motility Recordings in the Mouse Colon
The methodology has been described in detail previously
(Keating et al., 2010). Briefly, animals were euthanized as
described above, and a midline laparotomy was immediately
performed and the exposed abdomen bathed in Krebs solution
[in mM: 119 NaCl, 4.7 KCl, 1 NaH2PO4, 1.2 MgSO4, 25
NaHCO3, 2.5 CaCl2, 11 glucose] gassed with carbogen [95%
O2, 5% CO2]. The entire colon was removed and immediately
placed into a beaker of carbogen-gassed Krebs solution. Using
a syringe, the lumen was then cleared of any contents by
gentle flushing with Krebs solution. An adapted standard organ
bath procedure was used. Segments of colon (6 cm length)
were placed into the organ bath (20 mL volume) perfused
continuously (10 mL min−1) with 37◦C Krebs solution, gassed
with carbogen, and equilibrated to pH 7.4. The oral and aboral
ends of the colon segment were securely attached to an input
and output port of the organ bath, respectively. The input port
was connected to a reservoir and syringe set-up which allowed
the controlled perfusion of Krebs solution through the lumen
of the colonic segment, whilst the output port was attached
in series to a pressure transducer (BD DTXPlusTM, Oxford,
United Kingdom). Motor activity was initiated in the colon
segments by an infusion of Krebs from the syringe into the
lumen of the colon until an intraluminal pressure of ˜5 mmHg
had been reached. Under these conditions, regular aborally
propagating waves of contraction developed spontaneously and
persisted over time. These contractile waves were recorded as
changes in intraluminal pressure (Figure 1A) and were termed
CPMCs, similar to the normal peristaltic activity of the colon.
After an equilibration period of 40 min CPMC activity had
reached a consistent pattern, in terms of their amplitude and
frequency, and experimental procedures were then started. In a
small number of experiments (˜2%) tissues failed to show robust
CPMC-like activity and these were discarded from use before any
experimental procedures took place.
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FIGURE 1 | (A) Representative trace of basal murine colonic peristaltic motor complexes (CPMCs) recorded under basal conditions. The parameters used to
evaluate changes in motility are illustrated; a, the amplitude of individual CPMCs, (b1+b2+etc), the time in quiescence (TIQ) which is the total time the tissue is at
baseline activity during a 15 min (900 s) test period. The frequency represents the number of CPMC complexes measured during a 15 min time period. The dashed
line represents baseline intraluminal pressure. (B) Effect of the TRPA1 agonist ASP7663 (ASP) upon CPMC activity. The trace shows a representative recording of the
effects of cumulative additions of ASP7663 upon CPMC activity. ASP7663 reversibly decreased CPMC activity in a concentration-dependent fashion.
In vitro Bioassay: Experimental
Procedure
Compounds were bath applied using a cumulative concentration
response protocol consisting of successive 15 min perfusion
periods, starting with the vehicle and followed by 3 incremental
concentrations of a drug, followed by a washout period to assess
the reversibility of effects. In the experiments in which the TRPA1
antagonist HC-030031 was used to investigate the specificity of
TRPA1 agonist responses, the antagonist was added to the bath
for 15 min prior to the addition of the agonists.
CPMC Activity Quantification
CPMC activity was quantified using a set of three parameters
calculated for each 15 min experimental phase of the cumulative
concentration experiments. These were: CPMC frequency
(number of CPMCs/15 min), the time in quiescence (TIQ,
s), which is a measurement of the total time that the tissue
is at baseline activity during the 15 min period of drug or
vehicle perfusion and the average CPMC amplitude (mmHg)
(Figure 1A). The amplitude reflected the mechanical activity
of the tissue, whereas the TIQ reflected the overall time
with motor activity.
Data Analysis
Changes in intraluminal pressure generated by CPMC activity
were amplified (Digitimer, NL108, Welwyn Garden City,
United Kingdom) and subsequently acquired to a computer
through a CED 1401 interface and Spike2 software (Cambridge
Electronic Design, Cambridge, United Kingdom). Intraluminal
pressure was sampled at 100 Hz. Analysis was carried out off-
line using the software applications contained in the Spike2
software package. Data for TIQ and amplitude were also
expressed as percentage changes relative to their corresponding
vehicles (relative changes) and were compared to relative changes
in TIQ and amplitude calculated from time-matched vehicle
control experiments.
Statistical Analysis
Raw data are expressed as mean ± SEM; “n” refers to the
number of animals from which the data was obtained. Statistical
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analysis was performed using repeat measures one-way analysis
of variance (ANOVA) with Dunnet’s post hoc test as appropriate
(Prism 7.0, Graphpad software, San Diego, CA, United States).
Potential differences between agonist concentration response
curves in the absence and presence of antagonists were
determined using two-way ANOVA (Prism 7.0, Graphpad
software, San Diego, CA, United States). Significance was
achieved with a p < 0.05.
Drugs
Compounds were obtained from Sigma (Dorset,
United Kingdom), Tocris (Bristol, United Kingdom) and
Enzo Biosciences (Switzerland). Stock solutions of 1 or 10 mM
were prepared by adding an appropriate volume of either H2O or
DMSO and were diluted to test concentrations in Krebs solution.
4-hydroxy-2-nonenal was prepared as instructed and stored
in single aliquots at −80oC. Aliquots were thawed and diluted
into Krebs solution immediately before use. The maximum
concentration of DMSO used was 0.1%. Drugs were applied to
the serosal surface and while the bath concentrations of each
compound were not measured during the experiments, they
were assumed to reach a steady-state concentration equal to that
of the perfusate.
RESULTS
Colonic Peristaltic Motor Complex
(CPMC) Activity
CPMC activity was initiated in individual mouse colonic
segments via luminal infusion of Krebs solution and was
monitored experimentally as increases in intraluminal pressure
(Figure 1A) which propagated in an aboral direction along the
whole length of the colon. Baseline data on CPMC activity
(collected over a 15 min period from a total of 51 experiments) are
summarized as follows: frequency (the number of CPMCs/900 s),
8.2 ± 0.32; TIQ (time in quiescence), 563.4 ± 13 s; amplitude
(CPMC amplitude), 33± 1.8 mmHg.
The Effect of HC-030031 on CPMC
Activity
To determine whether TRPA1 played a role in regulating baseline
CPMC activity we tested whether CPMC activity could be
affected by a TRPA1 antagonist. We tested the effect of the
TRPA1 antagonist HC-030031(1–10 µM) on CPMC activity
and found that HC-030031 had no significant effect upon
baseline CPMC activity at any of the concentrations tested
(Supplementary Figure S1).
The Effect of ASP7663 on CPMC Activity
To determine whether TRPA1 agonists had any effect upon
CPMC activity we tested a range of compounds using a
cumulative dosing approach. ASP7663 (1–30µM) caused a
concentration dependent decrease in CPMC activity (Figure 1B)
shown as an increase in the TIQ (Figure 2A), a decrease in
frequency (Figure 2B) and a decrease in CPMC amplitude
FIGURE 2 | ASP7663 inhibited CPMC activity in mouse colonic segments.
(A–C). Graphs Illustrating the concentration dependent effects of ASP7663
(n = 4) on (A) TIQ (B) frequency, and (C) amplitude of CPMCs in mouse
colonic segments. The effects on ASP7663 upon CMPC frequency and TIQ
are reversible upon washout whereas ASP7663 irreversibly decreases CPMC
amplitude. (D–F) Graphs illustrating the effects of HC-030031 (10 µM) on
ASP7663 induced changes in (D) TIQ, (E) frequency, and (F) amplitude of
CPMCs. HC-030031 (n = 4) blocks the effects of ASP7663 on CPMC activity.
“ant” represents HC-030031, “V” represents vehicle, whilst “w” represents
activity after 45 min washout period in this and all subsequent figures. Data
are expressed as mean ± SEM; *p < 0.05 vs. (A–C) vehicle or (D–F)
antagonist by repeated measures one-way ANOVA.
(Figure 2C). It was noted that the effects of ASP7663 upon TIQ
and frequency reversed upon washout whereas the amplitude
changes were irreversible. Bath perfusion of HC-030031 (10
µM) blocked the effects of ASP7663 upon CPMC activity
(Figures 2D–F).
The Effect of Cinnamaldehyde on CPMC
Activity
We next tested the TRPA1 activator cinnamaldehyde (CMA)
for its effects on CPMC activity. CMA (10–100 µM) caused a
concentration dependent decrease in CPMC activity (Figure 3A)
in which both 30 and 100 µM CMA significantly increased TIQ
(Figure 3B) and decreased frequency (Figure 3C), whilst CPMC
amplitude was only decreased by 100 µM CMA (Figure 3D).
The inhibitory effects of CMA upon CPMC frequency and
TIQ were sustained into the late washout phase whereas the
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inhibitory effects of CMA upon CPMC amplitude reversed upon
washout (Figure 3D). HC-030031 blocked the effects of CMA
(Figures 3E–G) although in the presence of 10 µM HC-030031,
100 µM CMA still caused a significant reversible decrease in
CPMC frequency (Figure 3F).
The Effects of L-NAME on CMA Induced
Changes in CPMC Frequency
Studies have demonstrated that TRPA1 channels are expressed
on and activate inhibitory nitrergic neurons within the ENS
(Poole et al., 2011) and as such we examined the effects of
blocking nitrergic neurons upon CMA-evoked changes in CPMC.
Firstly, we tested the effects of NG-nitro-L-arginine methyl ester
(L-NAME) upon CPMC activity. L-NAME (100 µM) caused
a concentration dependent and significant increase in CPMC
activity, shown as a decrease in TIQ (Figure 6A) and an increased
frequency (Figure 6B). L-NAME had no effect upon CPMC
amplitude (Figure 6C). In the presence of 100 µM L-NAME, 10
µM, and 100 µM CMA had no significant effect upon CPMC
activity (Supplementary Figure S2).
The Effects of Allyl Isothiocyanate on
CPMC Activity
We tested the effects of the TRPA1 activator allyl isothiocyanate
(AITC) upon CPMC activity in isolated colonic segments. AITC
(10–100 µM) had a complex pattern of effects on CPMC activity
(Figures 4A–D). Ten and thirty micromolar AITC had no
effect upon CPMC activity whereas 100 µM AITC caused an
irreversible suppression of CPMC activity (Figures 4B–D). The
effects of AITC did not reverse upon washout, and the tissues
were unable to produce CPMC activity even after a 45 min
washout. The effects of AITC on CPMC activity were not blocked
by 10 µM HC-030031(Figures 4E–G).
The Effect of 4-Hydroxy-2-Nonenal on
CPMC Activity
The endogenous TRPA1 activator 4-hydroxy-2-nonenal (HNE)
was assessed for its effects on CPMC activity. HNE (1–10
µM) caused a sustained concentration dependent decrease
in CPMC activity shown as an increased TIQ (Figure 5A)
although frequency was not significantly affected by HNE at any
concentration tested (Figure 5B). Three and ten micromolar
HNE decreased CPMC amplitude (Figure 5C). Bath perfusion
of HC-030031 (10 µM) blocked the effects of HNE upon CPMC
activity (Figures 5D–F). Changes in TIQ in the absence of
changes in frequency could reflect altered CPMC width and as
such we analyzed the CPMC width in the absence and presence
of 10 µM HNE and found that the total CPMC width changed
from 330± 25 s (vehicle) to 249± 17.6 s (HNE) (p = 0.01, t-test).
Effects of HC-030031 on the Inhibitory
Actions of TPRA1 Agonists Upon CPMC
Activity
The effects of HC-030031 on TRPA1 agonist induced changes
in TIQ was assessed by plotting the percentage changes in
TIQ in the absence and presence of HC-030031. We found
significant differences in the dose response curves for CMA,
HNE and ASP7663 performed in the presence of 10 µM HC-
030031 compared to the presence of vehicle (Figures 6A–C)
(two-way ANOVA; F = 13.09, p = 0.001; F = 18.7, p = 0.0004;
F = 15.3, p = 0.001 for CMA, HNE and ASP7663, respectively).
However, the AITC induced changes in TIQ were not blocked
by HC-030031 at any concentration of AITC tested (Figure 6D)
(Two-way ANOVA; F = 0.16, p = 0.69).
Effect of TRPA1 Agonists on Relative
Changes in CPMC Activity
The actions of ASP7663, CMA and HNE upon CPMC amplitude
and TIQ were also plotted as percentage changes relative to their
vehicle responses (relative change) and were then compared to
appropriate time-matched controls (n = 6). At the highest drug
dose tested only CMA caused a significant relative decrease in
amplitude when compared against time- matched controls and
relative amplitude changes reversed by washout (Figures 7A,B).
Similar analysis for TIQ showed that all three compounds gave
rise to significant relative TIQ increases, but by the washout phase
the ASP7663 -induced relative increase in TIQ had reversed,
whilst both HNE and CMA-induced relative TIQ increases
were still elevated although only the CMA-induced effects were
significant (Figures 7C,D).
DISCUSSION
This study set out to examine the role of TRPA1 activation
in regulating colonic motility. We found that basal colonic
motility behavior is not dependent upon TRPA1 activity, but that
exogenous and endogenous TRPA1 agonists suppress colonic
motor behavior. This supports a role for neuronal TRPA1 in
regulating motor responses of the colon in response to dietary
or inflammatory generated TRPA1 agonists.
We employed an in vitro model of peristaltic-like behavior
(Abdu et al., 2002; Keating et al., 2014) to examine the role
of TRPA1 in regulating colonic motility. CPMC activity in
these preparations was invoked by a small distension of the
colonic segments which gave rise to reproducible changes in
contractile activity of the colon segments that were neurogenic
and myogenic in origin. We focused on analyzing changes
in amplitude, frequency and TIQ to assess the effects of
TRPA1 compounds on CPMC activity. Measuring amplitude
gave an indication of the compounds’ effects upon CPMC
contractility, while TIQ and frequency assessed the motor pattern
of CPMC activity (Keating et al., 2010). Our previous studies
have demonstrated TIQ to be a robust and stable marker of
CPMC frequency (Keating et al., 2010, 2014) reflecting the
neuronal influence of the ENS upon motility behavior in these
preparations and so we focused our analysis around this metric.
As support for this we found that the nitric oxide synthase
inhibitor L-NAME increased the TIQ of CPMC activity in these
preparations reflecting the pharmacological and physiological
actions of this compound on the ENS (Waterman and Costa,
1994; Rodríguez-Membrilla et al., 1995).
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FIGURE 3 | Cinnamaldehyde (CMA) inhibited CPMC activity. (A) Representative recording of the effects of cumulative additions of CMA upon CPMC activity. (B–D)
Graphs illustrating the concentration dependent effects of CMA (n = 7) on (B) TIQ, (C) frequency, and (D) amplitude of CPMCs in isolated mouse colonic segments.
CMA decreased CPMC activity in a concentration dependent fashion. The effects of CMA on frequency and TIQ do not reverse upon washout, whilst the inhibitory
effects of CMA upon CPMC amplitude are reversible. (E–G). Graphs illustrating the effects of HC-030031 (10 µM) on CMA induced changes in (E) TIQ; (F)
frequency, and (G) amplitude of CPMCs in isolated mouse colonic segments. HC-030031 (n = 5) attenuates the effects of CMA on CPMC activity. Data are
expressed as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. (B–D) vehicle or (E–G) antagonist by repeated measures one-way ANOVA.
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FIGURE 4 | Allyl isothiocyanate blocked CPMC activity in the isolated colon of mice. (A) Representative recording of the effects of cumulative additions of allyl
isothiocyanate (AITC) upon CPMC activity. (B–D) Graphs illustrating the concentration dependent effects of AITC (n = 6) on (B) TIQ (C) frequency and (D) amplitude
of CPMCs. 10 µM and 30 µM AITC had no effect on CPMC activity, but 100 µM AITC decreased frequency and increased TIQ whilst having no effect upon CPMC
amplitude. The effects of AITC on CPMC activity did not reverse upon washout and were not blocked by HC-030031 (10 µM). In the presence of 10 µM
HC-030031, 100 µM AITC decreased CPMC frequency and increased the TIQ in an irreversible fashion. (E–G) Graphs illustrating the effects HC-030031 on AITC
(n = 4) induced changes in (E) TIQ, (F) frequency, and (G) amplitude of CPMCs. Data are expressed as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. (B–D)
vehicle or (E–G) antagonist by repeated measures one-way ANOVA.
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FIGURE 5 | 4-hydroxy-2-nonenal inhibited CPMC activity in isolated segments
of mouse colon. In the presence of 4-hydroxy-2-nonenal (HNE) CPMC activity
is decreased (A–C). Graphs illustrating the effects of HNE (n = 4) on (A) TIQ,
(B) frequency, and (C) amplitude of CPMCs. In the presence of HNE CPMC
activity is decreased. (D–F). Graphs illustrating the effects HC-030031 on
HNE (n = 4) induced changes in TIQ (D); frequency (E); and amplitude (F) of
CPMCs. HC-030031 (10 µM) attenuates the effects of HNE on CPMC activity.
Data are expressed as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs.
(A–C) vehicle or (D–F) antagonist by repeated measures one-way ANOVA.
We were interested in assessing the role of TRPA1 channels in
regulating CPMC activity. TRPA1 has a unique gastrointestinal
expression pattern for a TRP channel in that as well as expression
in sensory neurons (Brierley et al., 2009) epithelial cells (Kaji
et al., 2012), and colonic mesenchymal cells (Yang et al., 2019),
it is also localized to inhibitory motor neurons, descending
interneurons, cholinergic neurons, and intrinsic primary afferent
neurons of the ENS (Poole et al., 2011) which are subtypes of
enteric neurons known to detect mechanical stimuli. Therefore
TRPA1 channels may act as mechanosensory channels within
enteric neurons controlling the activity of these neurons in
response to mechanical stimulation such as distension of the gut.
We found that in the presence of HC-030031 neither frequency
nor amplitude of CPMCs were altered suggesting that TRPA1
plays no obvious mechanosensory role in normal CPMC activity.
This supports data showing that TRPA1−/− mice possess normal
spontaneous motility (Poole et al., 2011) but contrasts with a
mechanosensory role for TRPA1 proposed in spinal afferents
whereby mechanically-induced inward currents in either DRG
neurites or cell bodies were reduced by TRPA1 deletion or
FIGURE 6 | Pharmacological inhibition of agonist-induced changes in CPMC
activity. The effect of HC-030031 on changes in TIQ induced by CMA, HNE,
ASP7663 and AITC. Exposure to HC-030031 (10 µM) significantly decreased
the dose response curves to (A) CMA, (B) HNE, (C) ASP7663. (D) Exposure
to HC-030031 (10 µM) had no effect on the dose response curve to AITC.
Data are expressed as mean ± SEM. Closed circles represent agonist alone
and closed squares represent agonist + antagonist. Data are expressed as
mean ± SEM; *p < 0.05. **p < 0.01. Curves were compared by using
two-way ANOVA with Bonferroni post hoc tests.
antagonism (Brierley et al., 2011). Furthermore TRPA1 channels
have been shown to be active in mechanosensory signaling in
extrinsic pathways in the gut (Brierley et al., 2009) and the
bladder (Nicholas et al., 2017). It’s unlikely that the concentration
of HC-030031 in these experiments was too low to have any
significant effect upon basal CPMC activity. Whilst HC-030031
is a relatively weak antagonist of murine TRPA1 channels
(pA2 ∼ 5.5; Ko et al., 2019) the antagonist was tested at an
upper concentration shown to be specific for blocking TRPA1
(Capasso et al., 2012) and to cause almost complete inhibition of
TRPA1 mediated Ca2+ currents in HEK cells expressing TRPA1
(McNamara et al., 2007).
If TRPA1 is not involved in regulating normal CPMC
mechanosensory function, what are the activators of TRPA1 in
the colon, and what are the effects of this activation upon CPMC
activity? We investigated this by using a series of ligands with
known actions on TRPA1. ASP7663, a synthetic TRPA1 agonist,
attenuated CPMC activity, and these effects were inhibited by
HC-030031. ASP7663 has been shown to increase Ca2+ currents
in HEK cells expressing human, rat, and mouse TRPA1 channels,
and stimulate 5-HT secretion from QGP-1 cells that are an EC
cell lineage expressing TRPA1 channels (Kojima et al., 2014),
thus demonstrating that this compound is a potent activator
of TRPA1 channels. Our results revealed ASP7663 inhibited
CMPC frequency, TIQ and amplitude that persisted into the
washout phase. Furthermore, these changes were blocked by a
TRPA1 antagonist suggesting that ASP7663 is acting via TRPA1
channels to mediate these inhibitory effects. However, we were
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FIGURE 7 | The effects of TRPA1 compounds on relative changes in TIQ and
amplitude. CPMC amplitude for HNE, CMA, and ASP7665 were plotted as
relative changes in amplitude at (A) their maximum dose compared to vehicle
and (B) washout compared to vehicle. Compounds are plotted alongside
appropriate time-matched vehicle control data (DMSO, n = 6). Similar analysis
for TIQ in which relative TIQ values for the test compounds are plotted
alongside appropriate time matched control data at (C) their maximum dose
compared to vehicle and (D) washout compared to vehicle. Data are
expressed as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. vehicle
by one-way ANOVA.
mindful of over interpreting the data concerning drug-induced
changes in amplitude as time-matched control experiments
also revealed a small but significant time-dependent change in
amplitude (Keating et al., 2014). This led to concerns that these
time-dependent amplitude changes were confounding the drug-
induced effects on this parameter, and so by plotting relative
changes in CPMC amplitude and TIQ and comparing these to
equivalent time-matched controls, we were able to control for
these confounding factors. Analyzing the data in this fashion
revealed that ASP7663 induced changes in CPMC activity only
affected TIQ showing that activation of TRPA1 channels inhibits
peristaltic-like behavior in the murine colon by acting on the
neuronal mechanisms underlying motility behavior.
If CPMC activity can be attenuated using a synthetic TRPA1
agonist it would seem likely that exogenous alimentary agonists
would act similarly. Therefore, we tested cinnamaldehyde
(CMA), and allyl isothiocyanate (AITC) for their effects on
CPMC activity. α, β- unsaturated aldehydes (CMA) and
isothiocyanates (AITC) both activate TRPA1 channels through
a process involving covalent modification of cysteine and lysine
residues located within the amino-terminal cytoplasmic region
of this channel. We found that CMA attenuated CPMC activity
in an HC-030031 dependant fashion, and this was seen clearly in
the rightward shift in the concentration response curve for CMA-
induced changes in TIQ in the presence of HC-030031. This
data identifies a role for TRPA1 induced signaling induced by an
exogenous agonist to regulate distension induced motor activity
in mouse colonic segments. We found that in contrast to the
ASP7663 effects on TIQ that CMA-induced long-lasting changes
in TIQ probably because modification of cysteine and lysine
side chains by reactive aldehydes such as CMA are essentially
irreversible (Aldini et al., 2007).
Our results with L-NAME demonstrated that the CMA
mediated activation of TRPA1 inhibited colonic motor activity
via a nitric oxide signaling pathway. TRPA1 channels have
been shown to be expressed on inhibitory nitrergic neurons
in the murine gastrointestinal tract (Poole et al., 2011) and
their inhibition, and subsequent depression of nitric oxide
synthesis, would have excitatory actions on CPMC activity
through the removal of basal inhibitory tone. Inhibition of
nitric oxide synthesis has been shown to have a prokinetic
effect on gastrointestinal tract function (Waterman and Costa,
1994; Rodríguez-Membrilla et al., 1995), and here we found
that L-NAME increased CPMC activity, but in the presence of
L-NAME we found that the inhibitory effects of CMA upon
CPMC activity were blocked suggesting that in this model CMA
activates TRPA1 channels on nitrergic expressing motorneurons
in the ENS to mediate inhibitory actions on motor activity.
AITC had complex effects upon CPMC activity, in which the
lowest concentrations had no effect upon CPMC activity, whilst
the highest concentration of AITC completely blocked CPMC
activity. Furthermore, these inhibitory effects of AITC could not
be reversed by HC-030031 which suggested that they were not
being mediated through TRPA1. Although studies have shown
that AITC activates gastrointestinal TRPA1 channels to mediate
secretion and contraction of tissue (Fothergill et al., 2016; Yang
et al., 2019) and that AITC can activate bladder afferents at similar
concentrations to those used in this study (Nicholas et al., 2017)
our results for AITC with HC-030031 supported no role for AITC
in mediating CPMC activity via activation of TRPA1 channels.
These results support previous data in which the inhibitory effects
of AITC on intestinal contractility were also resistant to blockade
by HC-030031 and were postulated to be due to AITC directly
acting on smooth muscle (Capasso et al., 2012). Furthermore
results from TRPA1−/− animals showed that AITC activates
calcium currents in myenteric neurons and mediates secretory
responses (Poole et al., 2011; Fothergill et al., 2016) further
demonstrating that AITC has small but viable off target effects
within the gastrointestinal tract. It is worth noting that AITC at
concentrations of 100 µM has been shown to be an agonist at
TRPV1 receptors and therefore exposure to the maximum dose
of AITC in these experiments could have desensitized TRPV1
channels expressed in the ENS, which could account for the
loss of CPMC activity that we observed. Further we are mindful
that intact colonic segments contain functional extrinsic afferent
terminals that express TRPV1 and TRPA1. Activation of these
mechanosensitive extrinsic afferents not only invokes central
signaling processes, but also localized responses that have been
implicated in controlling motor reflexes. It’s tempting to speculate
that perhaps desensitization of these mechanosensitive extrinsic
afferents accounted for the loss of CPMC activity in preparations
exposed to elevated AITC concentrations. Like TRPV1 channels
TRPA1 desensitize when exposed to agonists such as CMA or
AITC (Akopian et al., 2007), and as such the results obtained
with CMA and AITC could be due to direct desensitization of
TRPA1. However we found that concentrations of AITC that
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have been shown to activate TRPA1 had no effect upon CPMC
activity, whilst low concentrations of CMA decreased CPMC
activity in an HC-030031 dependent fashion suggesting that
modification of CPMC activity by lower concentrations of CMA
was through direct actions on TRPA1 channels expressed by
inhibitory neurons within the ENS.
We next asked whether endogenous activators of TRPA1
would affect CPMC activity and to explore this question we used
4-hydroxy-2-nonenal (HNE). Like CMA this compound is an
α, β-unsaturated aldehyde but HNE is an endogenous molecule
formed as a result of peroxidation of membrane phospholipids
in response to tissue injury, inflammation, and oxidative stress
(Esterbauer et al., 1991). Injections of HNE into rodent hind paws
have been shown to elicit long-lasting pain-related behaviors
that were inhibited by TRPA1 antagonists, and are absent in
TRPA1−/− animals demonstrating that HNE acts through a
TRPA1 channel mediated response (Trevisani et al., 2007).
We found that in addition to its role in promoting pain-like
behavior, HNE inhibited CPMC activity in a similar long-lasting
fashion specifically affecting TIQ when analyzed in terms of
relative changes in CPMC activity. This suggested that motor
activity in the colon could be regulated through the synthesis
of endogenous inflammatory markers acting via TRPA1 and
prompts consideration for an important role for TRPA1 within
the ENS as a sensor for inflammation.
The unique expression profile of TRPA1 in the intestine
suggests that signaling through this channel regulates multiple
processes. TRPA1 expression in enteric neurons clearly regulates
motility behavior via activation of inhibitory neurons whilst
mucosal expression of TRPA1 on enteroendocrine cells in the
small intestine signals the presence of nutrients within the
gut (Cho et al., 2014). TRPA1 expression is also found in
colonic enterocytes and mesenchymal cells where its activation
can induce ion secretion and smooth muscle contraction via
prostaglandin mediated processes (Kaji et al., 2012; Yang et al.,
2019). A role for TRPA1-mediated responses to inflammation
was proposed in a recent study showing that dextran sodium
sulfate (DSS) invoked inflammation of the rat colon led to
both an increased expression of HNE and abnormal colonic
contractions which could be attenuated with a TRPA1 antagonist
(Yang et al., 2019).
These results beg the question as to why we didn’t see
any elevated contractile events in our experiments. A simple
explanation for this is that our model measures a change in
intraluminal pressure caused by neurogenically orchestrated
waves of muscle contraction moving along the colonic segment
and as such our model would record changes in smooth muscle
contractility per se or increased secretion into the lumen as
increases in baseline intraluminal pressure which interestingly we
did see occur in preparations upon exposure to TRPA1 agonists
such as HNE although the changes were not significantly different
from control values. Also our drugs are added to the bathing
solution surrounding the tissue and diffuse into the tissue via
the serosa and consequently will reach the myenteric plexus
before the mucosa.
The role of mucosal TRPA1 signaling may be to detect
and respond to inflammation within the colon, but studies in
Drosophila have shown that colonization of the intestine by
pathogenic bacteria can activate contractions of the Drosophila
gut via a TRPA1 mechanism which may serve a protective
response to rid the intestine of harmful bacteria (Benguettat et al.,
2018). It would be interesting to see whether this novel pathway
is replicated in the mammalian gut and so would also implicate
TRPA1 as a sensor for the gastrointestinal microbiome.
In conclusion we have used an in-vitro model of colonic
motor activity to investigate the role of TRPA1 in regulating
colonic motility and found that TRPA1 channels play no role in
regulating basal distension induced motor activity in the mouse
colon, but when activated by either endogenous or exogenous
agonists acts in an inhibitory fashion to preferentially decrease
the frequency of CPMC activity. The endogenous ligands that
drive this process and the physiological signaling pathways that
underpin this channel’s function are a target for further research,
but it may well be that one of the roles of enteric TRPA1
activation is as a danger signal to reduce motility, and that
inflammatory and or microbiome signals could be the stimuli to
initiate this pathway.
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FIGURE S1 | Effects of HC-030031 upon baseline CPMC activity in the isolated
colon of mice. (A) Representative recording showing the effects of (Ai), vehicle
and (Aii) 10µM HC-030031 upon CPMC activity. CPMC activity is unchanged
in response to application of HC-030031. (B–D) Graphs illustrating the
concentration dependent effects of HC-030031 (n = 5) on (B) TIQ, (C) frequency,
and (D) amplitude of CPMCs. Data are expressed as mean ± SEM. In all
experiments there was no significant difference between the CPMC parameters
recorded in the presence of vehicle or HC-030031 (repeat measures
one-way ANOVA).
FIGURE S2 | Effects of L-NAME on CMA induced changes in CPMC activity in
isolated segments of mouse colon. In the presence of L-NAME CPMC activity is
unchanged in response to application of CMA. (A–C). Graphs illustrating the
concentration dependent effects of CMA in the presence of L-NAME (n = 5) on the
(A) TIQ, (B) frequency, and (C) amplitude of CPMCs. Data are expressed as
mean ± SEM; *p < 0.05; **p < 0.01 vs. L-NAME by repeated measures one-way
ANOVA.
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